Nuveen LLC Buys New Holdings in Maze Therapeutics, Inc. $MAZE

Nuveen LLC bought a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 11,375 shares of the company’s stock, valued at approximately $125,000.

Other large investors have also recently bought and sold shares of the company. TRV GP IV LLC acquired a new position in Maze Therapeutics in the first quarter valued at approximately $66,874,000. Alphabet Inc. acquired a new position in Maze Therapeutics in the first quarter valued at approximately $26,561,000. General Catalyst Group Management LLC acquired a new position in Maze Therapeutics in the first quarter valued at approximately $11,405,000. TRV GP V LLC acquired a new position in Maze Therapeutics in the first quarter valued at approximately $10,468,000. Finally, Harvard Management Co. Inc. acquired a new position in Maze Therapeutics in the first quarter valued at approximately $7,019,000.

Maze Therapeutics Stock Up 5.6%

Shares of MAZE stock opened at $15.88 on Monday. The stock has a 50 day simple moving average of $14.55 and a 200-day simple moving average of $12.01. Maze Therapeutics, Inc. has a 1-year low of $6.71 and a 1-year high of $19.19.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Wall Street Analysts Forecast Growth

MAZE has been the subject of a number of analyst reports. HC Wainwright initiated coverage on Maze Therapeutics in a report on Wednesday, July 23rd. They issued a “buy” rating and a $34.00 price target for the company. Wedbush initiated coverage on Maze Therapeutics in a report on Tuesday, July 8th. They issued an “outperform” rating and a $17.00 price target for the company. BTIG Research initiated coverage on Maze Therapeutics in a report on Tuesday, September 2nd. They issued a “buy” rating and a $30.00 price target for the company. Finally, Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and an average price target of $26.33.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.